2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

NCT03168100 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No study population. No subjects enrolled.

Conditions

Multiple Myeloma

Interventions

DRUG: Elotuzumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Bortezomib

Sponsor

University of Arkansas